Fortress Biotech, Inc.NASDAQ: FBIO

Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

· Issued by Fortress Biotech, Inc.

On 6ix: 6ix.com/news/fortress-biotech-announces-positive-topline-clinical-efficacy-results-for-cutx-101-copper-histidinate-for-the-treatment-of-menkes-disease

Watch Fortress Biotech's latest callFortress Biotech (NASDAQ:FBIO) Q3 2025 Earnings Call · Replay · Nov 12, 2025Read the transcript of Fortress Biotech (NASDAQ:FBIO) Q3 2025 Earnings Call

Statistically Significant Improvement in the Primary Endpoint of Overall Survival in Menkes Disease Patients who Received Early Treatment with CUTX-101, Compared to an Untreated Historical Control, with a Nearly 80% Reduction in the Risk of Death (Hazard Ratio = 0.21, p

Fortress Biotech, Inc. on 6ix

Story so far

Earlier from Fortress Biotech

Later from Fortress Biotech

All Fortress Biotech news releases